Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

NCT02701634 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG: ENTO
DRUG: Placebo

Sponsor

Gilead Sciences